pharmaphorum Daily newsletter - 20th Nov.
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
Mid-week brings a mix of industry developments, starting with more bad news for Sage Therapeutics , after its treatment for cognitive impairment associated with Huntington's disease failed in a phase 2 trial, spelling the end of the programme.
On a brighter note, Pfizer has secured European Commission approval for Hympavzi, a new once-weekly subcutaneous treatment for severe haemophilia A and B.
In other headlines, President-Elect Donald Trump has appointed controversial celebrity doctor Mehmet Oz (aka Dr Oz) to lead the Centers for Medicare & Medicaid Services , stirring varied reactions. While in the UK, The NICE - National Institute for Health and Care Excellence has blamed pricing issues for the collapse of talks over #Enhertu, leaving NHS patients unable to access this breast cancer drug.
Finally, MSD has reported that its subcutaneous formulation of #Keytruda matches the efficacy of the IV form, potentially offering patients a simpler cancer treatment option.
For those in search of a longer read this Wednesday, explore the top treatments, trials, and HCPs shaping the ESMO 2024 conversation on social media, and learn how the EMA is working to accelerate drug approvals in the EU.
All this and more on pharmaphorum.com
News
Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for cognitive impairment associated with Huntington's disease, spelling the end of the programme.
Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU
Donald Trump has chosen talk show host and celebrity doctor Dr Mehmet Oz to lead the Centers for Medicare and Medicaid Services
Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been abandoned, according to cost-effectiveness assessor NICE.
A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.
Views & Analysis
The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike.
Discover the latest treatments, clinical trials, and top healthcare professionals sharing insights on social media from the ESMO 2024 conference.
As Global Head of Oncology for IQVIA Biotech, Gerhard du Toit manages all aspects of oncology clinical trials, optimising strategies and enhancing delivery from early to late phases.
Recommended by LinkedIn
When talking about AI in pharma and life sciences marketing, we often focus on the automation of content creation, management, and delivery. No wonder, since effective content marketing has a significant impact on the way a company and its products are perceived by HCPs and patients. And AI can do a lot to enhance content processes. A new feature sponsored by Viseven explores the topic further.
Prepare for 2025 with pharmaphorum’s Life Sciences Industry Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends.
Podcasts & Videos
In today’s podcast, web editor Nicole Raleigh is joined by Jesse Mendelsohn, senior vice president of Model N’s Center of Excellence, for a conversation that explores multiple aspects of the drug pricing debate in America – speaking before President-Elect Donald Trump confirmed his nomination of Robert F Kennedy Jr as US Health and Human Services Secretary.
In a new podcast, web editor Nicole Raleigh speaks with Dr Samuel Ewing, global head of pharma partnerships at Doccla, about the next generation of digital tools such as wearable medical devices, as well as remote patient monitoring and digital healthcare generally.
In another pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Neal Kassell, chair and founder of the Focused Ultrasound Foundation and previously a neurosurgeon, who created the Foundation in 2006 to improve the lives of millions of people with serious medical disorders by accelerating the development and adoption of focused ultrasound.
In this pharmaphorum podcast, web editor Nicole Raleigh speaks with Matt Hollingsworth, co-founder and CEO of Carta Healthcare, a company seeking to support the healthcare data registry market by transforming a previously manual clinical data abstraction process.
In a new podcast, web editor Nicole Raleigh speaks with Dr Evan Floden, CEO and co-founder of Seqera, a data orchestration and genomics analysis company, about barriers of entry to genomic surveillance in public health labs and how these can be lowered to support future bioinformaticians, aiding acceleration and quality and accuracy in R&D.
Webinars & White Papers
Join us on Wednesday 4th December @ 2pm GMT - 3pm CET - 9am EST for an exclusive webinar, sponsored by Trueblue, to learn how life sciences organisations are leveraging the power of AI-driven strategic insights to revolutionise decision-making, enhance customer engagement, and gain a competitive edge.
In this webinar sponsored by PurpleLab, learn how to gain a competitive edge by understanding physician prescribing behaviour in target markets. Avilable now on demand.
In a webinar sponsored by Syneos Health - with Atlas Clinical Research’s Chief Executive Officer Mark Scullion, and Batisha Anson, Global Head of Patient Diversity and Health Equity at Syneos Health - learn more about the site experience for clinical research sites. Now available on demand.
Global reach, personal touch: Mastering customer engagement at scale Discover how to balance personalised engagement with regulatory compliance across global pharma markets in a webinar presented by EVERSANA INTOUCH. Available on demand now.
Beyond clinical: Boosting recruitment and retention with SDOH data In a Socially Determined sponsored webinar, discover how industry leaders are harnessing non-clinical data to enhance recruitment, retention, and broader evidence generation. Now available on demand.